Spero Therapeutics (SPRO) Receivables Refunds (2016 - 2022)
Spero Therapeutics posted quarterly Receivables Refunds of $39000.0 for Q3 2022, down 88.6% year-on-year from $342000.0 in Q3 2021, and up 105.26% on a QoQ basis from $19000.0 in Q2 2022.
Spero Therapeutics (SPRO) has 7 years of Receivables Refunds data on file, last reported at $39000.0 in Q3 2022.
- For the quarter ending Q3 2022, Receivables Refunds fell 88.6% year-over-year to $39000.0; the trailing twelve-month figure through Sep 2022 stood at $39000.0 (down 88.6% YoY), and the FY2021 full-year result was $361000.0, down 57.33% from the prior year.
- Receivables Refunds for Q3 2022 stood at $39000.0, up from $19000.0 in the prior quarter.
- Across five years, Receivables Refunds topped out at $1.9 million in Q1 2018 and bottomed at $19000.0 in Q2 2022.
- The 5-year median for Receivables Refunds is $786000.0 (2019), against an average of $766105.3.
- Peak annual rise in Receivables Refunds reached 401.35% in 2022, while the deepest fall reached 94.51% in 2022.
- A 5-year view of Receivables Refunds shows it stood at $922000.0 in 2018, then fell by 14.75% to $786000.0 in 2019, then increased by 7.63% to $846000.0 in 2020, then tumbled by 57.33% to $361000.0 in 2021, then sank by 89.2% to $39000.0 in 2022.
- The last three Receivables Refunds figures came in at $39000.0 (Q3 2022), $19000.0 (Q2 2022), and $371000.0 (Q1 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Refund Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 39,000.00 |
| Jun 30, 2022 | 19,000.00 |
| Mar 31, 2022 | 371,000.00 |
| Dec 31, 2021 | 361,000.00 |
| Sep 30, 2021 | 342,000.00 |
| Jun 30, 2021 | 346,000.00 |
| Mar 31, 2021 | 74,000.00 |
| Dec 31, 2020 | 846,000.00 |
| Sep 30, 2020 | 1.05 Mn |
| Jun 30, 2020 | 736,000.00 |
| Mar 31, 2020 | 712,000.00 |
| Dec 31, 2019 | 786,000.00 |
| Sep 30, 2019 | 1.43 Mn |
| Jun 30, 2019 | 921,000.00 |
| Mar 31, 2019 | 928,000.00 |
| Dec 31, 2018 | 922,000.00 |
| Sep 30, 2018 | 944,000.00 |
| Jun 30, 2018 | 1.83 Mn |
| Mar 31, 2018 | 1.90 Mn |
| Dec 31, 2017 | 1.93 Mn |
| Sep 30, 2017 | 1.00 Mn |
| Dec 31, 2016 | 100,000.00 |